ABCA1 cholesterol efflux & protein-protein interactions
ABCA1 cholesterol efflux & protein-protein interactions
批准号:
7267835
负责人:
MICHAEL Leo FITZGERALD
金额:
$37.33万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2009-07-31
关键词:
ATP HydrolysisATP-Binding Cassette TransportersAffinityAffinity ChromatographyAmino Acid TransporterAmino AcidsApolipoprotein A-IApolipoproteinsApolipoproteins AAtherosclerosisBiochemicalCardiovascular DiseasesCell membraneCellsCholesterolCholesterol EstersCholesterol HomeostasisChromosome MappingComplexConditionCoupledCytoplasmic TailDisease ProgressionDisruptionExcisionExhibitsGeneral PopulationGenesHelix (Snails)Hereditary DiseaseHigh Density LipoproteinsHomeostasisHumanIncidenceLipidsLiverMaintenanceMass Spectrum AnalysisMediatingMethodsModelingMolecularMusMutateMutationPathologicPatientsPeripheral Nervous System DiseasesPhenotypePhospholipidsPhosphoric Monoester HydrolasesPhosphotransferasesPhysiologicalPhysiologyPlayProcessProteinsProteomicsRateRegulationResearchResearch PersonnelRoleScaffolding ProteinSmall IntestinesSpecificitySterolsStructureTangier DiseaseTestingTherapeuticTissuesTonsilear helixinsightinterestmacrophagemutantnovelpreventprogramsprotein protein interactiontherapeutic target
中文摘要
描述(由申请人提供):细胞将胆固醇和磷脂外排至载脂蛋白,如载脂蛋白a - 1,作为维持全身脂质稳态过程的一部分。丹吉尔病是一种罕见的遗传病,以周围神经病变、早发心血管疾病和缺乏循环HDL为特征,证明了脂质外排的生理学重要性。遗传作图研究将丹吉尔表型与ATP结合盒转运体ABCA1的突变联系起来,随后的研究表明,ABCA1在HDL的形成中起着限速作用。在一般人群中,HDL水平升高与心血管疾病的发病率呈负相关,因此增加ABCA1活性的治疗可能有助于预防疾病进展。本提案的目的是描述定义ABCA1外排机制的关键结构-功能关系,以及蛋白质-蛋白质相互作用在决定ABCA1活性中的作用。这个广泛的目标集中在对自然发生的丹吉尔突变的分析上,这种突变删除了转运体的最后46个氨基酸。缺失的氨基酸是一个高度保守结构域的一部分,如本提案所示,对ABCA1外排活性至关重要。对缺失区域内其他合成突变体的分析定义了一个新的VFVNFA基序,该基序唯一地标识了ABCA转运蛋白的一个亚类。该基序对ABCA1活性至关重要,可以反式抑制外排活性。一种蛋白质组学方法已经被开发出来,其中ABCA1和感兴趣的突变体转运蛋白被亲和纯化,共同纯化的蛋白被质谱分析。描述了与VFVNFA基序相互作用的蛋白质,并将研究它们与外排机制的功能相关性。由于一系列相互作用似乎会下调外排活性,破坏这些相互作用可能会提供ABCA1外排增加的治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Cells efflux cholestrol and phospholids to apolipoproteins such as apoA-l as part of a process that maintains whole body lipid homeostatsis. The physiologic importance of lipid efflux is demonstrated by patients suffering from Tangier disease, a rare genetic condition characterized by peripheral neuropathy, premature cardiovascular disease and an absence of circulating HDL. Genetic mapping studies have associated the Tangier phenotype with mutations in the ATP binding cassette transporter ABCA1 and subsequent studies have shown that ABCA1 plays a rate limiting role in the formation of HDL. In the general population elevated HDL levels are inversely correlated with the incidence of cardiovascular disease, thus therapies that increase ABCA1 activity may help prevent disease progression. The objective of this proposal is to describe key structure-function relations that define the ABCA1 efflux mechanism and what role protein-protein interactions play in determining the activity of ABCA1. This broad aim is focused by the analysis of a naturally occurring Tangier mutation that deletes the last 46 amino acids of the transporter. The deleted amino acids are part of a highly conserved domain, and as shown in this proposal, are essential for ABCA1 efflux activity. Analysis of additional synthetic mutants within the deleted region has defined a novel VFVNFA motif that uniquely identifies a subclass of ABCA transporters. This motif is essential for ABCA1 activity and can act in trans to inhibit efflux activity. A proteomic approach has been developed in which ABCA1 and interesting mutant transporters are affinity purified and the co-purify proteins are analyzed by mass spectrometry. The proteins which interact with the VFVNFA motif are described and their functional relevance to the efflux mechanism investigated will be investigated. Since a set of the interactions appear to down-regulate efflux activity disruption of such interactions may offer therapeutic targets by which ABCA1 efflux can be increased.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetic Reprogramming in Atherosclerosis
-
批准号:9382567
-
项目类别:
-
资助金额:$69.05万
-
财政年份:2017
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
Epigenetic Reprogramming in Atherosclerosis
-
批准号:9914292
-
项目类别:
-
资助金额:$67.36万
-
财政年份:2017
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
HDL prevention of cholesterol crystal inflammation in HIV disease
-
批准号:8884627
-
项目类别:
-
资助金额:$60.29万
-
财政年份:2012
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
HDL prevention of cholesterol crystal inflammation in HIV disease
-
批准号:8221304
-
项目类别:
-
资助金额:$64.68万
-
财政年份:2012
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
HDL prevention of cholesterol crystal inflammation in HIV disease
-
批准号:8551689
-
项目类别:
-
资助金额:$59.34万
-
财政年份:2012
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
HDL prevention of cholesterol crystal inflammation in HIV disease
-
批准号:9098831
-
项目类别:
-
资助金额:$60.58万
-
财政年份:2012
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
ABCA1 cholesterol efflux & protein-protein interactions
-
批准号:7105050
-
项目类别:
-
资助金额:$38.45万
-
财政年份:2005
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
ABCA1 cholesterol efflux & protein-protein interactions
-
批准号:6922977
-
项目类别:
-
资助金额:$41.48万
-
财政年份:2005
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
ABCA1 cholesterol efflux & protein-protein interactions
-
批准号:7480213
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2005
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
FUNCTIONAL ANALYSIS OF THE TANGIER DISEASE GENE ABC1
-
批准号:6402737
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2001
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
FUNCTIONAL ANALYSIS OF THE TANGIER DISEASE GENE ABC1
-
批准号:6208198
-
项目类别:
-
资助金额:$4.43万
-
财政年份:2000
-
负责人:MICHAEL Leo FITZGERALD
-
依托单位:
海外基金